PPDライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 1月 1970 @ 09:00):

PPD, Inc. provides drug development services to the biopharmaceutical industry worldwide. The company operates through Clinical Development Services and Laboratory Services segments...

Stats
本日の出来高	1.87M
平均出来高	1.44M
時価総額	0.00
EPS	$0.430 ( 2021-10-27 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.151 (0.32%)

Insider Trading

Date	Person	Action	Amount	type
2021-12-08	Carlyle Group Inc.	Sell	55 722 733	Common Stock
2021-12-08	H&f Corporate Investors Vii, Ltd.	Sell	157 138	Common Stock
2021-12-08	Johnston David Michael	Buy	33 228	Stock Options (Right to Buy)
2021-12-08	Johnston David Michael	Buy	25 522	Common Stock
2021-12-08	Johnston David Michael	Sell	151 747	Stock Options (Right to Buy)

INSIDER POWER
0.00
Last 98 transactions
Buy: 2 703 151 \| Sell: 89 993 839

ボリューム相関

長: 0.17 (neutral)

短: 0.34 (neutral)

Signal:(54.867) Neutral

PPD Inc 相関

10 最も正の相関
IDLB	0.957
IVAC	0.957
KRMD	0.949
RNEM	0.948
ISEM	0.947
LYTS	0.947
TACT	0.946
BOCN	0.945
XOMAP	0.943
HTHT	0.941

10 最も負の相関
ASPS	-0.963
NKTX	-0.949
DSGN	-0.948
SWAV	-0.947
LGMK	-0.933
STRC	-0.933
LYRA	-0.932
RTPY	-0.93
PEAR	-0.929
AMGN	-0.929

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

PPD Inc 相関 - 通貨/商品

-0.37
( neutral )

0.50
( neutral )

0.00
( neutral )

0.05
( neutral )

-0.48
( neutral )

0.37
( neutral )

PPD Inc 財務諸表

Annual	2020
収益:	$4.68B
総利益:	$1.80B (38.42 %)
EPS:	$0.350

FY	2020
収益:	$4.68B
総利益:	$1.80B (38.42 %)
EPS:	$0.350

FY	2019
収益:	$4.03B
総利益:	$1.62B (40.24 %)
EPS:	$0.161

FY	2018
収益:	$3.75B
総利益:	$1.47B (39.32 %)
EPS:	$0.300

Financial Reports:

No articles found.

PPD Inc

PPD, Inc. provides drug development services to the biopharmaceutical industry worldwide. The company operates through Clinical Development Services and Laboratory Services segments. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company was founded in 1985 and is headquartered in Wilmington, North Carolina.